Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Companion diagnostic (CDx)
EGFR mutation
EGFR-TKI
next-generation sequencing (NGS)
polymerase chain reaction (PCR)
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
10
2020
revised:
05
12
2020
accepted:
07
12
2020
pubmed:
3
2
2021
medline:
20
11
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been approved. In our institute, the CDx test for EGFR-TKIs was changed from the Therascreen test (Therascreen) to the Cobas EGFR v2 test (Cobas) because only Cobas was approved for the use of osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with T790M mutations. The clinical influence of switching the CDx test has not yet been examined comprehensively. All serial patients with lung cancer tested for EGFR mutations with CDx tests between February 2014 and February 2016 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) were enrolled in this analysis. Therascreen was used as a CDx test for EGFR-TKI therapy in 607 patients between February 2014 and January 2015, and Cobas was used in 621 patients between February 2015 and February 2016. EGFR mutations were detected in 218 patients (35.9%) and 244 patients (39.3%) tested with Therascreen and Cobas, respectively. At the initial diagnosis, 400 and 459 patients were tested with Therascreen and Cobas, respectively. EGFR mutation subtypes, including del19, L858R, and others, were detected in 13.0%, 17.0%, and 2.5% of patients using Therascreen and 17.4%, 14.4%, and 1.5% of patients using Cobas, respectively. No significant impact of switching from Therascreen to Cobas as the CDx test for EGFR mutations in clinical practice was observed. However, the detection pattern of the EGFR mutation subtypes between the two CDx tests was slightly different. SIGNIFICANT FINDINGS OF THE STUDY: We examined the influence of changing the EGFR test in 1228 patients in total. The detection rate of EGFR mutations was similar. However, the detection pattern for EGFR subtype mutations was slightly different between the two tests. Switching CDx tests from target polymerase chain reaction (PCR)- to next-generation sequencing (NGS)-based methods may lead to obvious changes in clinical practice. When the CDx test is required to change, the investigation of this influence is warranted in future studies.
Sections du résumé
BACKGROUND
Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been approved. In our institute, the CDx test for EGFR-TKIs was changed from the Therascreen test (Therascreen) to the Cobas EGFR v2 test (Cobas) because only Cobas was approved for the use of osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with T790M mutations. The clinical influence of switching the CDx test has not yet been examined comprehensively.
METHODS
All serial patients with lung cancer tested for EGFR mutations with CDx tests between February 2014 and February 2016 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) were enrolled in this analysis.
RESULTS
Therascreen was used as a CDx test for EGFR-TKI therapy in 607 patients between February 2014 and January 2015, and Cobas was used in 621 patients between February 2015 and February 2016. EGFR mutations were detected in 218 patients (35.9%) and 244 patients (39.3%) tested with Therascreen and Cobas, respectively. At the initial diagnosis, 400 and 459 patients were tested with Therascreen and Cobas, respectively. EGFR mutation subtypes, including del19, L858R, and others, were detected in 13.0%, 17.0%, and 2.5% of patients using Therascreen and 17.4%, 14.4%, and 1.5% of patients using Cobas, respectively.
CONCLUSIONS
No significant impact of switching from Therascreen to Cobas as the CDx test for EGFR mutations in clinical practice was observed. However, the detection pattern of the EGFR mutation subtypes between the two CDx tests was slightly different.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: We examined the influence of changing the EGFR test in 1228 patients in total. The detection rate of EGFR mutations was similar. However, the detection pattern for EGFR subtype mutations was slightly different between the two tests.
WHAT THIS STUDY ADDS
Switching CDx tests from target polymerase chain reaction (PCR)- to next-generation sequencing (NGS)-based methods may lead to obvious changes in clinical practice. When the CDx test is required to change, the investigation of this influence is warranted in future studies.
Identifiants
pubmed: 33528892
doi: 10.1111/1759-7714.13797
pmc: PMC7952781
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
906-913Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Clin Oncol. 2005 May 10;23(14):3235-42
pubmed: 15886311
Jpn J Clin Oncol. 2016 May;46(5):462-7
pubmed: 26977054
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
J Clin Pathol. 2013 May;66(5):381-5
pubmed: 23386666
Mol Cancer Ther. 2013 Feb;12(2):220-9
pubmed: 23371856
Respirology. 2013 Nov;18(8):1261-70
pubmed: 23796143
Ann Oncol. 2019 Dec 1;30(12):1978-1984
pubmed: 31553438
Lung Cancer. 2014 Mar;83(3):329-33
pubmed: 24439568
Cancer Sci. 2013 Nov;104(11):1396-400
pubmed: 23991695
Br J Cancer. 2014 May 27;110(11):2812-20
pubmed: 24743704
Cancer Sci. 2011 May;102(5):1032-7
pubmed: 21272159
Ann Oncol. 2012 Nov;23(11):2914-2919
pubmed: 22776705
Oncol Lett. 2018 Jul;16(1):1087-1094
pubmed: 30061936
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Clin Cancer Res. 2012 Jun 15;18(12):3470-7
pubmed: 22510346
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Oncotarget. 2017 Jul 8;8(35):59552-59562
pubmed: 28938658
Lung Cancer. 2020 Aug;146:236-243
pubmed: 32590236
Clin Chim Acta. 2014 Feb 15;429:8-11
pubmed: 24269715
Diagn Mol Pathol. 2013 Dec;22(4):190-5
pubmed: 24193010
Ann Oncol. 2013 Jan;24(1):54-9
pubmed: 22967997
Ann Oncol. 2017 Nov 1;28(11):2715-2724
pubmed: 28945865
Expert Rev Mol Diagn. 2016 Dec;16(12):1251-1257
pubmed: 27737606
J Clin Oncol. 2008 Dec 1;26(34):5589-95
pubmed: 18794545
Lung Cancer. 2016 Nov;101:1-8
pubmed: 27794396
Lung Cancer. 2014 Nov;86(2):170-3
pubmed: 25214431